7,047 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Bought by Palumbo Wealth Management LLC

Palumbo Wealth Management LLC purchased a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the third quarter, HoldingsChannel reports. The fund purchased 7,047 shares of the company’s stock, valued at approximately $223,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in IDEAYA Biosciences by 82.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,249 shares of the company’s stock worth $515,000 after acquiring an additional 7,356 shares during the period. abrdn plc acquired a new stake in IDEAYA Biosciences during the 3rd quarter worth about $7,376,000. Mirae Asset Global Investments Co. Ltd. lifted its position in IDEAYA Biosciences by 35.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock worth $94,000 after acquiring an additional 796 shares during the period. Allworth Financial LP lifted its position in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 800 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in IDEAYA Biosciences during the 3rd quarter worth about $74,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock traded down $0.46 on Thursday, hitting $29.00. The company’s stock had a trading volume of 38,044 shares, compared to its average volume of 845,655. IDEAYA Biosciences, Inc. has a 1 year low of $25.54 and a 1 year high of $47.74. The firm has a fifty day moving average price of $33.57 and a 200-day moving average price of $37.15. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -14.66 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). During the same period in the prior year, the firm posted ($0.50) earnings per share. As a group, analysts forecast that IDEAYA Biosciences, Inc. will post -2.48 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a report on Monday, July 29th. JPMorgan Chase & Co. decreased their price objective on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Oppenheimer reissued an “outperform” rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday. Finally, Wedbush decreased their price objective on IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating for the company in a report on Tuesday, September 24th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $55.45.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.